Radionuclide agents

Sr, as the strontium ion (Sr2+), is used for pain palliation in patients with metastatic bone disease. The strontium ion is a calcium ion mimic, being taken up in metabolically active bone such as cancer. 89Sr is a therapeutic radionuclide with a half-life of 50.53 days, emitting a 1.49 MeV [3 particle on decay. Several recent reviews discuss the use of radionuclides and their complexes as pain palliation agents in metastatic bone disease.18,212-215... 

Fig. 10. Typical chelating agents for radionuclides having the ability for further derivatization with biomolecules for targeted delivery.

The full exploitation of the wide range of oxidation states of rhenium in radiopharmaceutical design requires not only a wide range of ligand donor types with varied n-donor and acceptor properties, but also suitable reducing agents to provide access to oxidation levels below (VII). This is because for radiopharmaceutical purposes the most conveniently man-factured form of rhenium radionuclides is perrhenate. The traditional routes to reduced rhenium complexes are not particularly amenable to use in a radiopharmaceutical context, where mild, rapid, and preferably... 

Hollinger, M.A. (1985). Mucokinetic agents, radionuclides, and anticoagulant-thrombolytic agents. In Respiratory Pharmacology and Toxicology. W. B. Saunders, Philadelphia, pp. 133-134. 

What radionuclides or chemical/biological agents now contaminate the patient ... 

---